Researchers at Mass General Brigham engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five immunomodulators, and avoids healthy brain tissue. A single ...

Preoperative radiation boosted antitumor immunity and treatment response in HR positive, HER2 negative breast cancer in the phase II P RAD trial presented at SABCS 2025. When combined with ...

Presented at the 2025 SABCS annual meeting, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease recurrence or death by 30% in early-stage ER-positive ...

One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali plus endocrine therapy, according to MONALEESA data presented at SABCS 2025.

The FDA has granted accelerated approval to sevabertinib (Hyrnuo), for previously treated HER2-mutated metastatic non-squamous non-small cell lung cancer, based on strong activity in the Phase I/II ...

A large AI-driven study of 3,476 cancer patients, presented at ESMO 2025, reveals that thymic health is strongly linked to immunotherapy success. Patients with higher thymic scores had a 35% lower ...

Currently being evaluated in the pivotal VAPOR 2 clinical trial, the Vanquish system offers a minimally invasive approach that targets cancer with precision while preserving surrounding tissue. With ...

The Phase III SUNMO trial could mark a breakthrough for transplant-ineligible patients with relapsed or refractory large B-cell lymphoma. In this ONCOLife interview, we spoke with Dr. Jason Westin, ...

The START Center for Cancer Research has announced a strategic partnership with Advarra to accelerate and streamline early-phase oncology trials across its global network. By integrating Advarra’s ...

In this exclusive interview, Dr. Neal Shore, Founder and Medical Director of the Carolina Urologic Research Center (CURC), describes how the center pioneers new clinical research strategies for ...

Presented at ASCO 2025, new post-hoc analyses from the Phase III ARANOTE trial showed that darolutamide (Nubeqa) plus ADT extended the time to HRQoL deterioration by 5.1 months and delayed pain ...

The data from the Phase III OASIS-4 trial, presented at ASCO25, showed that elinzanetant significantly reduced the frequency and severity of hot flashes associated with endocrine therapy for breast ...